$27.95
+3.4%Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
LBRX • NASDAQ
| LB Pharmaceuticals Inc Common Stock Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
OPERATING ACTIVITIES | ||||
-25.2M | -63.1M | -6.3M | -14.3M | |
321K | 91K | 4K | 2K | |
0.0 | 3.2M | 295K | 431K | |
3.3M | 3.5M | -4.8M | 11.1M | |
(0.0) | (1K) | (1K) | (1K) | |
-13.7M | 3.3M | -1.3M | 86K | |
-35.2M | -53.1M | -12.1M | -2.7M | |
INVESTING ACTIVITIES | ||||
-52K | -769K | -25K | (0.0) | |
-44.8M | -29.7M | -34M | (0.0) | |
5M | 53.7M | 6M | 123K | |
-39.9M | (23.2M) | -28M | (123K) | |
FINANCING ACTIVITIES | ||||
302.6M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 725K | 25M | |
0.0 | -1.7M | -2M | -2.9M | |
302.6M | 38.3M | 33.7M | 23M | |
CASH FLOW SUMMARY | ||||
-272K | 0.0 | 0.0 | 0.0 | |
227.2M | 8.5M | -6.4M | 20.4M | |
23M | 15M | 21.4M | 1M | |
250.2M | 23.5M | 15M | 21.4M | |
-35.3M | -53.8M | -12.1M | -2.7M |
LBRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 03, 2026 | 2026 | |
S-1 S-1 N/A | April 06, 2026 | April 06, 2026 | ||
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 05, 2026 | February 04, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 10, 2025 | 2025 |
Continue your LBRX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.